This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. JCO. 2022;25;JCO.21.02112.
Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol. 2022;8:871–8.
Usui Y, Taniyama Y, Endo M, Koyanagi YN, Kasugai Y, Oze I, et al. Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer. N Engl J Med. 2023;388:1181–90.
Wineland D, Le AN, Hausler R, Kelly G, Barrett E, Desai H, et al. Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers. JCO Precis Oncol. 2023;7:e2300036.
Benusiglio PR, Fallet V, Sanchis-Borja M, Coulet F, Cadranel J. Lung cancer is also a hereditary disease. Eur Respir Rev. 2021;30:210045.
Ji X, Mukherjee S, Landi MT, Bosse Y, Joubert P, Zhu D, et al. Protein-altering germline mutations implicate novel genes related to lung cancer development. Nat Commun. 2020;11:2220.
Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, et al. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA Netw Open. 2022;5:e2213070.
Diossy M, Sztupinszki Z, Borcsok J, Krzystanek M, Tisza V, Spisak S, et al. A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures. npj Precis Onc. 2021;5:1–8.
Rifkin AS, Less EM, Wei J, Shi Z, Zheng SL, Helfand BT, et al. Association of Reported Candidate Monogenic Genes With Lung Cancer Risk. Clin Lung Cancer. 2023;24:313–21.
Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023;34:215–27.
Patel AP, Wang M, Fahed AC, Mason-Suares H, Brockman D, Pelletier R, et al. Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. JAMA Netw Open. 2020;3:e203959.
Li S, Silvestri V, Rebbeck TR, Neuhausen SL, Hopper JL, Nielsen HR, et al. Reply to V. Fallet et al. JCO. 2022;40:2509–10.
Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. Lancet. 2023;401:390–408.
Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093–112.
No specific funding was involved.
PRB has received honoraria from AstraZeneca and MSD, the manufacturers or olaparib, a drug that targets BRCA2-deficient cancers.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Benusiglio, P.R., Dardenne, A., Fallet, V. et al. Emerging cancer risks in BRCA2 pathogenic germline variant carriers. Eur J Hum Genet 31, 1355–1356 (2023). https://doi.org/10.1038/s41431-023-01465-y